Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Lung Neoplasms 17Neoplasms 14Carcinoma 9Neoplasm Metastasis 7Thoracic Neoplasms 4NSCLC 4Colorectal Neoplasms 4Respiratory Tract Neoplasms 3Respiratory Tract Diseases 3Neoplasms by Site 3Lung Diseases 3Bronchial Neoplasms 3Brain Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumor 2Noonan Syndrome 2Neoplasms, Nerve Tissue 2Neoplasms by Histologic Type 2Meningeal Carcinomatosis 2Head and Neck Neoplasms 2Carcinoma, Bronchogenic 2Breast Neoplasms 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1T790M Positive NSCLC Patients 1Stomach Neoplasms 1

Interventions

Paclitaxel 18pembrolizumab 16Cisplatin 16Fluorouracil 15Irinotecan 13tislelizumab 9Oxaliplatin 8Nivolumab 8Docetaxel 8Leucovorin 6Capecitabine 5spartalizumab 4Levoleucovorin 4Carboplatin 4lenvatinib 3durvalumab 3Radiotherapy 3Drug Therapy 3toripalimab 2sintilimab 2regorafenib 2elgemtumab 2atezolizumab 2Itraconazole 2Injections 2Gemcitabine 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tremelimumab 1sitravatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Esophageal Squamous Cell Carcinoma × osimertinib × Clear all
NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Merus B.V.

Phase 1/2 Active not recruiting
194 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡